Nasdaq OMX

Nuvaira, Inc

Del

Nuvaira Announces Enrollment Completion in First Sham-Controlled Clinical Trial of Targeted Lung Denervation for COPD

MINNEAPOLIS, June 27, 2017 (GLOBE NEWSWIRE) -- Nuvaira  (formerly known as Holaira), a developer of medical devices to treat obstructive lung diseases, today announced completion of patient enrollment in the AIRFLOW-2  trial, the first sham-controlled clinical trial of Targeted Lung Denervation* (TLD) using the Nuvaira(TM) Lung Denervation System in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The AIRFLOW-2 (NCT#02058459 ) trial, designed to assess the safety of TLD in patients suffering from moderate to severe COPD at 16 institutions throughout Western Europe, included 82 patients. 

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4d6d7093-874c-4cac-b8a4-14c7275b566f

COPD  is one of the leading causes of morbidity and mortality worldwide. It is characterized by a persistent airflow limitation due to a progressive narrowing of the airways interfering with normal breathing that results in shortness of breath (dyspnea), wheezing, chest tightness, and a productive cough.

"Completing the first randomized, sham-controlled clinical trial of Targeted Lung Denervation is an important milestone to ensure the integrity of scientific data as Nuvaira works to develop a new treatment option for COPD patients," said Jim Pavliska , vice president of Clinical Affairs at Nuvaira. "We are very pleased with the ongoing feedback from the 16 institutions participating in the AIRFLOW-2 trial, as it is providing key insights into optimizing patient selection and procedure workflow for our upcoming pivotal trial, AIRFLOW-3."

The Nuvaira Lung Denervation System is a catheter-based system used to treat the overactive airway nerves during TLD. It is a one-time bronchoscopic procedure  that uses the dNerva(TM) Dual Cooled Radiofrequency catheter to provide ablative therapy that opens obstructed airways to improve breathing, and has the potential to provide lasting, whole-lung improvement in patients with moderate to severe COPD.

"We are encouraged by our experience in the AIRFLOW-2 trial using the Nuvaira System," said Professor Felix Herth, M.D., Ph.D., FCCP, chairman, Division of Pulmonology and Respiratory Care Medicine, Thoraxklink, University of Heidelberg. "Because COPD is a progressive disease that affects millions of people and places a significant financial burden on the system, it is imperative that we find better methods of treatment. This new COPD technology may offer a true breakthrough for patients by providing long-term clinical improvement from a one-time procedure," continued Professor Herth.

"TLD is the first medical procedure that targets the whole lung by bronchoscopically disrupting overactive parasympathetic nerves to promote airway dilatation to make it easier to breathe," said Dirk-Jan Slebos, M.D., Ph.D., study principal investigator, University Medical Center, Groningen, The Netherlands. "Our previous research indicates that using Nuvaira's Lung Denervation System is feasible and safe, and there is evidence for a working therapy. In the current study we compared two groups of COPD patients in a sham-controlled manner to show safety and feasibility while separating treatment effect from any placebo effect. Details of the study will be discussed during the September ERS meeting in Milan, Italy."

About COPD
COPD  is the umbrella term used to describe a group of diseases such as small airway disease (chronic bronchitis) and emphysema, characterized by chronic and incompletely reversible airway obstruction that interferes with normal breathing. It is estimated that COPD affects 4 to 10 percent of all adults in European countries and more than 300 million people globally1,2.

Pharmacological treatment is the approach for most patients today. Inhaled drugs are used once or twice daily to relax and temporarily open airways. Other forms of treatment include pulmonary rehabilitation, oxygen administration and surgical intervention. These treatments provide temporary relief. The annual financial burden of lung disease in Europe is €141 billion and COPD accounts for almost half3. In the United States, COPD costs are estimated to be more than $50 billion annually4.

About Nuvaira
Nuvaira  (formerly known as Holaira) is a privately held company headquartered in Minneapolis, Minn. The company is developing the Nuvaira(TM) Lung Denervation System to address chronic obstructive pulmonary disease (COPD) by treating the overactive airway nerves during Targeted Lung Denervation* (TLD). Nuvaira received CE Mark approval for its Nuvaira Lung Denervation System for use during TLD in January 2016. More information may be found at www.Nuvaira.com .

Institutions Participating in the AIRFLOW-2 Clinical Trial:

Institution Principal Investigator at Site Country
1.  AKH Linz  Bernd Lamprecht, MD  Austria
2.  Otto Wagner Spital  Arschang Valipour, MD**  Austria
3.  CHRU de Lille-Hôpital Calmette  Thierry Perez, MD  France
4.  CHU de Grenoble - Hôpital Michallon  Christoph Pison, MD  France
5.  CHU de Paris - Hôpital Bichat Claude Bernard  Armelle Marceau, MD  France
6.  CHU de Reims - Hôpital Maison Blanche  Gaetan Deslee, MD  France
7.  CHU de Strasbourg - Nouvel Hôpital Civil  Romain Kessler, MD  France
8.  Asklepios-Fachkliniken Munchen Gauting  Wolfgang Gesierich, MD  Germany
9.  Charite-Universitatsmedizin Berlin  Ralf-Harto Huebner, MD  Germany
10. Klinikverbund Kempten Oberallgäu  Christian Schumann, MD  Germany
11. Ruhrlandklinik Essen  Kaid Darwiche, MD  Germany
12. Thoraxklinik Heidelberg  Felix Herth, MD  Germany
13. Universitätsklinikum Bonn  Dirk Skowasch, MD  Germany
14. Academic Medical Center  Peter Bonta, MD  The Netherlands
15. University Medical Center Groningen  Dirk-Jan Slebos, MD**  The Netherlands
16. Royal Brompton & Harefield NHS Foundation Trust  Pallav Shah, MD  United Kingdom

*  Targeted Lung Denervation (TLD) is currently under clinical investigation for chronic obstructive pulmonary disease and is not yet commercially available.

** AIRFLOW-2 Trial Principal Investigators

Nuvaira is a trademark of Nuvaira, Inc.

_____________________________
1 Global Chronic Obstructive Pulmonary Disease Epidemiology and Patient Flow - 2017. Fore Pharma. 
http://www.efanet.org/get-advice/copd  
http://www.efanet.org/get-advice/copd  
4 Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Report

Media Contact:
Shane Gleason
Nuvaira
+1 (703-772-3035)
sgleason@Nuvaira.com 


WEB:https://www.nuvaira.com/

Information om Nasdaq OMX

Nasdaq OMX
Nasdaq OMX
Nikolaj Plads 6
1007 København K

+45 3377 0377http://globenewswire.com